This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Haemonetics Corporation
11/5/2026
Hello, and welcome to Hemonetics Corporation's second quarter 2027 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to turn the call over to Olga Guyette. You may begin.
Good morning and thank you for joining us for Humanetics second quarter fiscal year 2027 conference call and webcast. I'm joined today by Chris Simon, our CEO, and James D'Arecca, our CFO. This morning reported second quarter and first half fiscal 2027 results and updated our fiscal 2027 guidance. Our earnings release, Supplemental presentation and related materials are available in the Investor Relations section of our website. Before we begin, I'd like to remind everyone that we will use both reported and organic revenue growth rates that exclude the impact of FX, the exit of certain liquid solution products, and our fiscal year 2027 guidance is also adjusted for the impact of the 53rd week. We'll also refer to other non-GAAP financial measures to help investors understand Humanetics' ongoing business performance. Please note that these measures exclude certain charges and income items. A full list of excluded items, reconciliations to our GAAP results, and comparisons with the prior year periods are provided in our earnings release. Our remarks today include forward-looking statements and our actual results may differ materially from the anticipated results. Factors that may cause our results to differ include those referenced in the Safe Harbor Statement in today's earnings release, and our other SEC filing. We did not undertake an obligation to update this forward-looking statement. And now, I'd like to turn it over to Chris.
Good morning, everyone. Thank you for joining us. We delivered a strong quarter and first half with growth across plasma, blood management and interventional technologies. Organic revenue growth was 10% in the second quarter and 8% in the first half and adjusted earnings per share was $1.35 in the quarter and $2.49 in the first half, growing 6% in both periods. Beyond these strong results, we reached several important milestones that position us for future growth. We expanded our CSL relationship, secured key regulatory approvals, and launched innovative Med-Surg products. These achievements reflect years of investment in our technology, our customer relationships, and our execution. Let's discuss our business results. MedSurg delivered a solid quarter of broad-based growth, increasing 6% organically in both the second quarter and first half. Blood management technologies grew 7% organically in the quarter and 8% in the first half. Within BMT, hemostasis management growth was driven by greater account penetration, higher tag utilization, and continued share gains. The TAG 5000 capital upgrade cycle is winding down, but durable growth is being driven by mid-teens recurring TAG 6S disposables growth. Transfusion management revenue grew well into the double digits in both periods, becoming an increasingly meaningful contributor to the franchise. With our evolving portfolio, we are building our high-margin recurring revenue base while giving customers greater flexibility to adopt integrated software solutions that improve workflow automation, transfusion safety, and traceability. This growth was partially offset by cell salvage. Interventional technologies grew 3% organically in both the second quarter and first half, sustaining the return to growth established in Q1. Vascular closure led performance with Fascade MVP and MVP XL growing in the low double digits in electrophysiology in both periods. Strong demand and improved commercial execution are driving greater utilization and share gains as the underlying market stabilizes. Vascular closure momentum was partially offset by a challenging prior year comparison in esophageal cooling. We also advanced our growth strategy through several important milestones. We extended Vascaid MVP XL globally with initial CE mark certification and Japanese regulatory approval for the expanded indication. We launched the PACE Pro Guidewire, broadening our structural heart guidewire portfolio with a solution designed to improve procedural efficiency within familiar physician workflows. And we received US FDA approval for Percocel Elite, extending our vascular closure offering into large four structural heart and endovascular procedures. While these initiatives are not expected to materially contribute to FY27 revenue, they leverage our existing commercial infrastructure to broaden our market reach and strengthen our runway for sustained long-term growth. Strong first half execution, improving momentum in interventional technologies and new product launches reinforce our confidence and the business's growth trajectory and significant long-term opportunity. However, we remain disciplined in our outlook, relying on demonstrated progress to inform our guidance. Therefore, we are reaffirming our fiscal 2027 MedSurg organic revenue growth guidance of mid single digits. Turning to apheresis, organic revenue grew 14% in the second quarter and 10% in the first half. Within that, Plasma grew 18% and 13% respectively, driven by prior share gains, strong underlying collections, and the rollout of Persona Plus. Second quarter global Plasma collections grew in the high single digits. Continuous long-term investment in our technology and our service delivery has helped us to gain share and accelerate adoption of our integrated platform. Persona Plus strengthens our offering by increasing plasma yield, improving center productivity, and lowering customers' cost per liter. The rollout is on schedule with substantial adoption across our customer base. Our expanded CSL relationship further validates the superiority of our value proposition. We are scaling capacity to supply CSL while supporting continued strong demand across our customer base. We anticipate completing the rollout of Nexus PCS with Persona Plus to all of CSL's US plasma centers before the end of calendar 2027. Continued Persona Plus adoption and additional share gains create multi-year durable growth with benefits extending beyond the initial implementations. We remain committed to advancing our technological advantage by investing in new capabilities that improve customer economics and the donor experience. Other apheresis was flat in the quarter and down modestly in the first half as strength in red cell collection was offset by order timing and continued portfolio rationalization. We are raising fiscal 2027 apheresis organic revenue growth guidance to high single digits from low to mid single digits, reflecting stronger first half performance Persona Plus Adoption, and formally confirmed CSL center conversions through Q3, partially offset by a modest decline in other apheresis. Consistent with our prior outlook, we have not factored in any incremental revenue contribution from second half plasma collections growth, and we expect our second half growth to be weighted towards Q4, reflecting certain contractual economics. We anticipate additional CSL share in our fourth quarter. However, we will wait until specific rollout plans are confirmed to incorporate that into our guidance. Our total company revenue first half results and greater visibility into customer commitments across our business support an increase in our fiscal 2027 revenue outlook. We now expect organic growth of six to nine percent, up from four to seven percent. and reported growth of 8% to 11%, up from 5% to 8%. We enter the second half with multiple catalysts to propel revenue growth ahead of our markets and the potential to accelerate earnings growth as we capture these opportunities. We are focused on executing customer conversions, advancing new product adoption and scaling to meet growing demand. We are turning durable growth into lasting value.
You're reading a preview of the HAE Q2 2027 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing